Faraz Mahmood Ali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Faraz Mahmood Ali has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Yule Finlay
Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK
22 shared publications - Sam Salek
School of Health, Medicine and Life Sciences, University of Hertfordshire, Hatfield, UK
19 shared publications - John Robert Ingram
Division of Infection & Immunity, Cardiff University , Cardiff
12 shared publications - Rubina Shah
Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK
11 shared publications - Kennedy Otwombe
Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
8 shared publications - Jeffrey Roy Johns
Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK
4 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 518
Equivalence of measurement properties of the Dermatology Life Quality Index (DLQI) across 13 European countries
The Dermatology Life Quality Index (DLQI) is the most widely used tool to measure burden of skin diseases and assess intervention effectiveness. It is embedded in national guidelines and disease registries in > 45 countries and available in > 138 translations. This study examined psychometric properties of the DLQI across 13 European languages. 3,408 patients had completed the DLQI questionnaire with no missing data. Confirmatory factor analysis (CFA) was performed using datasets of each country and multigroup CFA (MGCFA) across all countries. Known-group analysis was performed of DLQI sum-score against physician-assessed severity by country. All countries’ DLQI data showed essential unidimensionality with good fits to a 1-factor CFA model with CFI, TLI unscaled values all > 0.97 (COSMIN criteria). MGCFA indicated different country translations of the DLQI conceptualize the same construct and showed equality of factor loadings. Although, scalar invariance was not seen, meaning that direct comparison of mean DLQI scores across 12 countries is not supported by the current results, partial scalar invariance was achieved after constraining one threshold for DLQI item 7. Known-group analysis of DLQI versus disease severity was significant for every country (all p < 0.025). Good psychometric properties were present across all 13 languages examined with essential unidimensionality confirmed. The DLQI differentiated between levels of disease severity and EQ-5D-3 L levels across all these languages. This adds further confidence in the appropriateness of using the DLQI with this range of languages.
- 12 October 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 518
Open AccessEquivalence of measurement properties of the Dermatology Life Quality Index (DLQI) across 13 European countries
The Dermatology Life Quality Index (DLQI) is the most widely used tool to measure burden of skin diseases and assess intervention effectiveness. It is embedded in national guidelines and disease registries in > 45 countries and available in > 138 translations. This study examined psychometric properties of the DLQI across 13 European languages. 3,408 patients had completed the DLQI questionnaire with no missing data. Confirmatory factor analysis (CFA) was performed using datasets of each country and multigroup CFA (MGCFA) across all countries. Known-group analysis was performed of DLQI sum-score against physician-assessed severity by country. All countries’ DLQI data showed essential unidimensionality with good fits to a 1-factor CFA model with CFI, TLI unscaled values all > 0.97 (COSMIN criteria). MGCFA indicated different country translations of the DLQI conceptualize the same construct and showed equality of factor loadings. Although, scalar invariance was not seen, meaning that direct comparison of mean DLQI scores across 12 countries is not supported by the current results, partial scalar invariance was achieved after constraining one threshold for DLQI item 7. Known-group analysis of DLQI versus disease severity was significant for every country (all p < 0.025). Good psychometric properties were present across all 13 languages examined with essential unidimensionality confirmed. The DLQI differentiated between levels of disease severity and EQ-5D-3 L levels across all these languages. This adds further confidence in the appropriateness of using the DLQI with this range of languages.
- Open Access
- 8 April 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (3) , 518-528
Beyond the burden: Measuring the quality of life impact of Parkinson's on family members/partners using FROM-16
Background: Family members of people with Parkinson's disease (PwP) often experience significant burden and poor quality of life (QoL). However, existing research predominantly centres on caregiver burden, with limited exploration of the broader impact of Parkinson's disease (PD) on family QoL. Aim: To measure the impact of a person's PD on the QoL of their family members and partners using the validated generic Family Reported Outcome Measure-16 (FROM-16). Methods: A cross-sectional study recruited online UK family members/partners of PwP through patient support groups to complete the FROM-16. Results: 152 family members/partners (mean age=67 years, median=70, SD = 10.9; females=106) of patients (mean age=72.3, median=74, SD = 8.5; females=55) with PD completed the FROM-16. The FROM-16 mean total score was 15.3 (SD = 7.9), with 45% of family members/partners having a score ≥17, meaning “a very large effect” on QoL of family members. A significant predictor of family impact was if the patient was male. The most impacted areas were feeling worried, sad, and frustrated, and the impact on holiday, family activities, sleep and sex life. Conclusions: A person's PD greatly impacts the QoL of their family members/partners. Their well-being has important implications for supporting PwP and nursing home placement, hence the need to measure this impact to provide tailored support to these family members/partners. FROM-16 could be used to measure the family impact of PD in the routine practice of different settings.
- 8 April 2026
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (3) , 518-528
Open AccessBeyond the burden: Measuring the quality of life impact of Parkinson's on family members/partners using FROM-16
Background: Family members of people with Parkinson's disease (PwP) often experience significant burden and poor quality of life (QoL). However, existing research predominantly centres on caregiver burden, with limited exploration of the broader impact of Parkinson's disease (PD) on family QoL. Aim: To measure the impact of a person's PD on the QoL of their family members and partners using the validated generic Family Reported Outcome Measure-16 (FROM-16). Methods: A cross-sectional study recruited online UK family members/partners of PwP through patient support groups to complete the FROM-16. Results: 152 family members/partners (mean age=67 years, median=70, SD = 10.9; females=106) of patients (mean age=72.3, median=74, SD = 8.5; females=55) with PD completed the FROM-16. The FROM-16 mean total score was 15.3 (SD = 7.9), with 45% of family members/partners having a score ≥17, meaning “a very large effect” on QoL of family members. A significant predictor of family impact was if the patient was male. The most impacted areas were feeling worried, sad, and frustrated, and the impact on holiday, family activities, sleep and sex life. Conclusions: A person's PD greatly impacts the QoL of their family members/partners. Their well-being has important implications for supporting PwP and nursing home placement, hence the need to measure this impact to provide tailored support to these family members/partners. FROM-16 could be used to measure the family impact of PD in the routine practice of different settings.
- Open Access
- 9 May 2025
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 9 (1) , 1-13
Psychometric validation of the Spanish for Ecuador Family Reported Outcome Measure (FROM-16) and its application to measure impact on family members of patients with skin diseases
Background: The Family Reported Outcome Measure (FROM-16) is a generic tool to measure the impact of health conditions on patients’ family members and partners (FMs). This study aimed to translate, validate, evaluate, and implement FROM-16 in Ecuadorian Spanish and to assess the quality of life (QoL) of FMs of patients with skin diseases. Methods: A cross-sectional study of patients and their FMs was performed using FROM-16 and a five-point-Likert scale to evaluate patient´s skin health by the FM and physician. Construct validity, confirmatory factor analysis and item response modelling of FROM-16 were assessed. Results: 195 FMs completed Ecuadorian FROM-16. Inter-item correlation was 0.40 and factor analysis confirmed the original two-factor model: Cronbach’s alpha 0.89, with factor loadings of 0.44–0.76. Mean age of patients = 41.8 ± 31.1 years and of FMs = 47.3 ± 7; diseases were classified as inflammatory (n = 88) or non-inflammatory (n = 107). The mean FROM-16 score was 12.5 ± 7 meaning “a moderate effect on QoL;” however, scores of 29.2% (57 of 195) indicated a “very large” (n = 47) or “extremely large” (n = 10) effect. Populations with the highest burden were adult children main carers, not cohabiting with their sick parents (mean FROM-16 = 17 ± 7.7, n = 8, p = 0.05 versus those cohabiting), and FM of patients with inflammatory conditions (mean = 14 ± 6.9, n = 88, p = 0.006 versus those with non-inflammatory dermatoses). Conclusion: The FROM-16 is a succinct, well-structured two-domain instrument. It can be used to identify the largely overlooked impact on FMs of dermatology patients. Understanding this impact may contribute to better holistic care, inform physicians’ decisions, and encourage further support for families.
- 9 May 2025
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 9 (1) , 1-13
Open AccessPsychometric validation of the Spanish for Ecuador Family Reported Outcome Measure (FROM-16) and its application to measure impact on family members of patients with skin diseases
Background: The Family Reported Outcome Measure (FROM-16) is a generic tool to measure the impact of health conditions on patients’ family members and partners (FMs). This study aimed to translate, validate, evaluate, and implement FROM-16 in Ecuadorian Spanish and to assess the quality of life (QoL) of FMs of patients with skin diseases. Methods: A cross-sectional study of patients and their FMs was performed using FROM-16 and a five-point-Likert scale to evaluate patient´s skin health by the FM and physician. Construct validity, confirmatory factor analysis and item response modelling of FROM-16 were assessed. Results: 195 FMs completed Ecuadorian FROM-16. Inter-item correlation was 0.40 and factor analysis confirmed the original two-factor model: Cronbach’s alpha 0.89, with factor loadings of 0.44–0.76. Mean age of patients = 41.8 ± 31.1 years and of FMs = 47.3 ± 7; diseases were classified as inflammatory (n = 88) or non-inflammatory (n = 107). The mean FROM-16 score was 12.5 ± 7 meaning “a moderate effect on QoL;” however, scores of 29.2% (57 of 195) indicated a “very large” (n = 47) or “extremely large” (n = 10) effect. Populations with the highest burden were adult children main carers, not cohabiting with their sick parents (mean FROM-16 = 17 ± 7.7, n = 8, p = 0.05 versus those cohabiting), and FM of patients with inflammatory conditions (mean = 14 ± 6.9, n = 88, p = 0.006 versus those with non-inflammatory dermatoses). Conclusion: The FROM-16 is a succinct, well-structured two-domain instrument. It can be used to identify the largely overlooked impact on FMs of dermatology patients. Understanding this impact may contribute to better holistic care, inform physicians’ decisions, and encourage further support for families.
- Open Access
- 1 April 2025
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 11 (2)
Multiple sclerosis greatly impacts family members/partners: Evidence using the Family Reported Outcome Measure (FROM-16)
Background: Multiple sclerosis (MS) may have a major impact on the physical, social and psychological wellbeing of people with multiple sclerosis (pwMS) and their family members/partners. Aim: To measure the impact of a person's MS on the quality of life of their family members/partner, and the associates of impact among family members, using a validated generic family-specific quality of life instrument, the Family Reported Outcome Measure (FROM-16). Methods: An online cross-sectional study was conducted to recruit family members/partners of pwMS through UK patient support groups. Results: A total of 219 family members/partners (mean age = 49.3 years, SD = 13.7; females = 55.3%) of pwMS (mean age = 50.1, SD = 12.5; females = 56.6%) completed the FROM-16. The FROM-16 mean total score was 16.9 (SD = 7.8), indicating ‘a very large effect’ on family members’ quality of life. The increasing age of pwMS, being a male person with MS, and being a female carer were significant predictors of family impact. 50.7% of family members had FROM-16 scores ≥17. Spouses/partners (170/219) of pwMS reported a significant impact on their sex life compared to other relationships ( p < 0.001). Conclusion: MS substantially impacts the quality of life of family members/partners of pwMS, indicating a need to assess this impact routinely. The FROM-16 could be used to measure the MS family impact in routine practice to support family members appropriately and to include this impact in health economic appraisal and therapeutic clinical trials.
- 1 April 2025
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 11 (2)
Open AccessMultiple sclerosis greatly impacts family members/partners: Evidence using the Family Reported Outcome Measure (FROM-16)
Background: Multiple sclerosis (MS) may have a major impact on the physical, social and psychological wellbeing of people with multiple sclerosis (pwMS) and their family members/partners. Aim: To measure the impact of a person's MS on the quality of life of their family members/partner, and the associates of impact among family members, using a validated generic family-specific quality of life instrument, the Family Reported Outcome Measure (FROM-16). Methods: An online cross-sectional study was conducted to recruit family members/partners of pwMS through UK patient support groups. Results: A total of 219 family members/partners (mean age = 49.3 years, SD = 13.7; females = 55.3%) of pwMS (mean age = 50.1, SD = 12.5; females = 56.6%) completed the FROM-16. The FROM-16 mean total score was 16.9 (SD = 7.8), indicating ‘a very large effect’ on family members’ quality of life. The increasing age of pwMS, being a male person with MS, and being a female carer were significant predictors of family impact. 50.7% of family members had FROM-16 scores ≥17. Spouses/partners (170/219) of pwMS reported a significant impact on their sex life compared to other relationships ( p < 0.001). Conclusion: MS substantially impacts the quality of life of family members/partners of pwMS, indicating a need to assess this impact routinely. The FROM-16 could be used to measure the MS family impact in routine practice to support family members appropriately and to include this impact in health economic appraisal and therapeutic clinical trials.
- Open Access
- 1 April 2025
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 105, adv43472
Uncovering the Life-long Impact of Skin Disease on Major Life Changing Decisions
- 1 April 2025
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 105, adv43472
Open AccessUncovering the Life-long Impact of Skin Disease on Major Life Changing Decisions
- Open Access
- 15 January 2025
- Published by Springer Nature
Systematic Reviews of Systematic Reviews and Meta-Analyses Including Use of the DLQI v1
There are a substantial number of published systematic reviews and meta-analyses on the use of the Dermatology Life Quality Index (DLQI). Of the 3,776 results found in PubMed by searching for “DLQI” or "dermatology life quality index" (filtered for “systematic review” or “meta-analysis”), 142 are categorised as systematic reviews, and 89 as meta-analyses. Likewise, searching Ovid-EMBASE found 9804 results for the DLQI, of which 532 are tagged as systematic reviews and 310 meta-analyses. Searching SCOPUS found 6607 results with 417 systematic reviews and 265 meta-analyses (all searches 24/10/24). Although the DLQI is the most widely used outcome measure internationally in dermatology, there is currently no source of information to give current and future users of the DLQI structured access to reviewed studies and meta-analyses.
- 15 January 2025
- Published by Springer Nature
Open AccessSystematic Reviews of Systematic Reviews and Meta-Analyses Including Use of the DLQI v1
There are a substantial number of published systematic reviews and meta-analyses on the use of the Dermatology Life Quality Index (DLQI). Of the 3,776 results found in PubMed by searching for “DLQI” or "dermatology life quality index" (filtered for “systematic review” or “meta-analysis”), 142 are categorised as systematic reviews, and 89 as meta-analyses. Likewise, searching Ovid-EMBASE found 9804 results for the DLQI, of which 532 are tagged as systematic reviews and 310 meta-analyses. Searching SCOPUS found 6607 results with 417 systematic reviews and 265 meta-analyses (all searches 24/10/24). Although the DLQI is the most widely used outcome measure internationally in dermatology, there is currently no source of information to give current and future users of the DLQI structured access to reviewed studies and meta-analyses.
- Open Access
- 24 November 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (2) , 652-662
Comparison of the impact of type 1 and type 2 diabetes on quality of life of families of patients: A UK cross‐sectional study
Aim: To measure the impact of type 1 and 2 diabetes mellitus (T1D and T2D) on the QoL of a person's family members/partner and assess if there is any difference in family impact. Methods: A cross‐sectional study, recruited online through patient support groups, involved UK family members/partners of people with diabetes completing the Family Reported Outcome Measure‐16 (FROM‐16). Results: Two hundred and sixty‐one family members/partners (mean age = 57.9 years, SD = 13.8; females = 68.2%) of people with diabetes (mean age = 57.7, SD = 20.6; females = 38.3%; T1D n = 100; T2D n = 161) completed the FROM‐16. The overall FROM‐16 mean score was 10.47, SD = 7.8, suggesting a moderate effect on the QoL of family members of people with diabetes. A quarter (24.5%) of family members experienced a ‘very large effect’ or ‘extremely large effect’ on their QoL. The family impact of T1D (mean FROM‐16 = 12.61, SD = 7.9) was greater than that of T2D (mean = 9.15, SD = 7.5, p < 0.01), with being ‘female’ and ‘parents of children and adolescents’ rendered as significant predictors of greater impact. Family members of T2D had a lower risk of experiencing a high family impact (FROM‐16 score >16) compared with T1D (RR 0.561, 95% CI 0.371–0.849). Conclusions: Compared to T2D, family members of T1D experience a greater impact on their QoL, particularly those caring for children and adolescents. These findings have clinical and resource implications, indicating a need to assess this impact as a part of routine diabetes care to support impacted family members. The FROM‐16 could assess this impact in routine practice and further facilitate referral of family members to appropriate support services.
- 24 November 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (2) , 652-662
Open AccessComparison of the impact of type 1 and type 2 diabetes on quality of life of families of patients: A UK cross‐sectional study
Aim: To measure the impact of type 1 and 2 diabetes mellitus (T1D and T2D) on the QoL of a person's family members/partner and assess if there is any difference in family impact. Methods: A cross‐sectional study, recruited online through patient support groups, involved UK family members/partners of people with diabetes completing the Family Reported Outcome Measure‐16 (FROM‐16). Results: Two hundred and sixty‐one family members/partners (mean age = 57.9 years, SD = 13.8; females = 68.2%) of people with diabetes (mean age = 57.7, SD = 20.6; females = 38.3%; T1D n = 100; T2D n = 161) completed the FROM‐16. The overall FROM‐16 mean score was 10.47, SD = 7.8, suggesting a moderate effect on the QoL of family members of people with diabetes. A quarter (24.5%) of family members experienced a ‘very large effect’ or ‘extremely large effect’ on their QoL. The family impact of T1D (mean FROM‐16 = 12.61, SD = 7.9) was greater than that of T2D (mean = 9.15, SD = 7.5, p < 0.01), with being ‘female’ and ‘parents of children and adolescents’ rendered as significant predictors of greater impact. Family members of T2D had a lower risk of experiencing a high family impact (FROM‐16 score >16) compared with T1D (RR 0.561, 95% CI 0.371–0.849). Conclusions: Compared to T2D, family members of T1D experience a greater impact on their QoL, particularly those caring for children and adolescents. These findings have clinical and resource implications, indicating a need to assess this impact as a part of routine diabetes care to support impacted family members. The FROM‐16 could assess this impact in routine practice and further facilitate referral of family members to appropriate support services.
- Open Access
- 7 November 2024
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 104, adv41120
A Systematic Review of 207 Studies Describing Validation Aspects of the Dermatology Life Quality Index
This study systematically analysed peer-reviewed publications describing validation aspects of the Dermatology Life Quality Index (DLQI) and used Naicker’s Critically Appraising for Antiracism Tool to assess risk of racial bias. Seven online databases were searched from 1994 until 2022 for articles containing DLQI validation data. Methodology followed PRISMA guidelines, the protocol was registered in PROSPERO, and articles reviewed independently by two assessors. Of 1,717 screened publications, 207 articles including 58,828 patients from > 49 different countries and 41 diseases met the inclusion criteria. The DLQI demonstrated strong test–retest reliability; 43 studies confirmed good internal consistency. Twelve studies were performed using anchors to assess change responsiveness with effect sizes from small to large, giving confidence that the DLQI responds appropriately to change. Forty-two studies tested known-groups validity, providing confidence in construct and use of the DLQI over many parameters, including disease severity, anxiety, depression, stigma, scarring, well-being, sexual function, disease location and duration. DLQI correlation was demonstrated with 119 Patient Reported Outcomes/Quality of Life measures in 207 studies. Only 15% of studies explicitly recruited minority ethnic participants; 3.9% stratified results by race/ethnicity. This review summarizes knowledge concerning DLQI validation, confirms many strengths of the DLQI and identifies areas for further validation.
- 7 November 2024
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 104, adv41120
Open AccessA Systematic Review of 207 Studies Describing Validation Aspects of the Dermatology Life Quality Index
This study systematically analysed peer-reviewed publications describing validation aspects of the Dermatology Life Quality Index (DLQI) and used Naicker’s Critically Appraising for Antiracism Tool to assess risk of racial bias. Seven online databases were searched from 1994 until 2022 for articles containing DLQI validation data. Methodology followed PRISMA guidelines, the protocol was registered in PROSPERO, and articles reviewed independently by two assessors. Of 1,717 screened publications, 207 articles including 58,828 patients from > 49 different countries and 41 diseases met the inclusion criteria. The DLQI demonstrated strong test–retest reliability; 43 studies confirmed good internal consistency. Twelve studies were performed using anchors to assess change responsiveness with effect sizes from small to large, giving confidence that the DLQI responds appropriately to change. Forty-two studies tested known-groups validity, providing confidence in construct and use of the DLQI over many parameters, including disease severity, anxiety, depression, stigma, scarring, well-being, sexual function, disease location and duration. DLQI correlation was demonstrated with 119 Patient Reported Outcomes/Quality of Life measures in 207 studies. Only 15% of studies explicitly recruited minority ethnic participants; 3.9% stratified results by race/ethnicity. This review summarizes knowledge concerning DLQI validation, confirms many strengths of the DLQI and identifies areas for further validation.
- Open Access
- 1 October 2024
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
- Vol. 38 (4) , 338-343
Dementia and Its Profound Impact on Family Members and Partners
Introduction: Dementia can adversely affect the quality of life (QoL) of family members/partners of those affected. Measuring this often-neglected burden is critical to planning and providing appropriate support services. This study measures this impact using the Family-Reported Outcome Measure (FROM-16). Methods: A large UK cross-sectional online study through patient research platforms, recruited family members/partners of people with dementia, to complete the FROM-16. Results: Totally, 711 family members/partners (mean age=58.7 y, SD=12.5; females=81.3%) of patients (mean age=81.6, SD=9.6; females=66.9) with dementia completed the FROM-16. The FROM-16 mean total score was 17.5 (SD=6.8), meaning “a very large effect” on QoL of family members, with females being more adversely impacted. Conclusions: Dementia profoundly impacts the QoL of family members/partners of patients. Routine use of FROM-16 could signpost provision of care support, reducing family members’ burnout. Such routine data could be used in economic analysis of the burden of dementia as well as in predicting institutionalization.
- 1 October 2024
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
- Vol. 38 (4) , 338-343
Open AccessDementia and Its Profound Impact on Family Members and Partners
Introduction: Dementia can adversely affect the quality of life (QoL) of family members/partners of those affected. Measuring this often-neglected burden is critical to planning and providing appropriate support services. This study measures this impact using the Family-Reported Outcome Measure (FROM-16). Methods: A large UK cross-sectional online study through patient research platforms, recruited family members/partners of people with dementia, to complete the FROM-16. Results: Totally, 711 family members/partners (mean age=58.7 y, SD=12.5; females=81.3%) of patients (mean age=81.6, SD=9.6; females=66.9) with dementia completed the FROM-16. The FROM-16 mean total score was 17.5 (SD=6.8), meaning “a very large effect” on QoL of family members, with females being more adversely impacted. Conclusions: Dementia profoundly impacts the QoL of family members/partners of patients. Routine use of FROM-16 could signpost provision of care support, reducing family members’ burnout. Such routine data could be used in economic analysis of the burden of dementia as well as in predicting institutionalization.
- Open Access
- 5 April 2024
- Published by Wiley in European Journal of Haematology
- Vol. 113 (1) , 117-126
Measurement of the major ignored burden of multiple myeloma, pernicious anaemia and of other haematological conditions on partners and family members: A cross‐sectional study
Background: Having a haematological condition can adversely affect the quality of life (QoL) of family members/partners of patients. It is important to measure this often ignored burden in order to implement appropriate supportive interventions.Objective: To measure current impact of haematological conditions on the QoL of family members/partners of patients, using the Family Reported Outcome Measure‐16 (FROM‐16).Methods: A cross‐sectional study, recruited online through patient support groups, involved UK family members/partners of people with haematological conditions completing the FROM‐16.Results: 183 family members/partners (mean age = 60.5 years, SD = 13.2; females = 62.8%) of patients (mean age = 64.1, SD = 12.8; females = 46.4%) with 12 haematological conditions completed the FROM‐16. The FROM‐16 mean total score was 14.0 (SD = 7.2), meaning ‘a moderate effect on QoL’. The mean FROM‐16 scores of family members of people with multiple myeloma (mean = 15.8, SD = 6.3, n = 99) and other haematological malignancies (mean = 13.9, SD = 7.8, n = 29) were higher than of people with pernicious anaemia (mean = 10.7, SD = 7.5, n = 47) and other non‐malignant conditions (mean = 11, SD = 7.4, n = 56, p < .01). Over one third (36.1%, n = 183) of family members experienced a ‘very large effect’ (FROM‐16 score>16) on their quality of life.Conclusions: Haematological conditions, in particular those of malignant type, impact the QoL of family members/partners of patients. Healthcare professionals can now, using FROM‐16, identify those most affected and should consider how to provide appropriate holistic support within routine practice.
- 5 April 2024
- Published by Wiley in European Journal of Haematology
- Vol. 113 (1) , 117-126
Open AccessMeasurement of the major ignored burden of multiple myeloma, pernicious anaemia and of other haematological conditions on partners and family members: A cross‐sectional study
Background: Having a haematological condition can adversely affect the quality of life (QoL) of family members/partners of patients. It is important to measure this often ignored burden in order to implement appropriate supportive interventions.Objective: To measure current impact of haematological conditions on the QoL of family members/partners of patients, using the Family Reported Outcome Measure‐16 (FROM‐16).Methods: A cross‐sectional study, recruited online through patient support groups, involved UK family members/partners of people with haematological conditions completing the FROM‐16.Results: 183 family members/partners (mean age = 60.5 years, SD = 13.2; females = 62.8%) of patients (mean age = 64.1, SD = 12.8; females = 46.4%) with 12 haematological conditions completed the FROM‐16. The FROM‐16 mean total score was 14.0 (SD = 7.2), meaning ‘a moderate effect on QoL’. The mean FROM‐16 scores of family members of people with multiple myeloma (mean = 15.8, SD = 6.3, n = 99) and other haematological malignancies (mean = 13.9, SD = 7.8, n = 29) were higher than of people with pernicious anaemia (mean = 10.7, SD = 7.5, n = 47) and other non‐malignant conditions (mean = 11, SD = 7.4, n = 56, p < .01). Over one third (36.1%, n = 183) of family members experienced a ‘very large effect’ (FROM‐16 score>16) on their quality of life.Conclusions: Haematological conditions, in particular those of malignant type, impact the QoL of family members/partners of patients. Healthcare professionals can now, using FROM‐16, identify those most affected and should consider how to provide appropriate holistic support within routine practice.